Genomics in active surveillance and post-prostatectomy patients: A review of when and how to use effectively
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Active surveillance is a preferred management strategy for low-risk prostate cancer (PCa). Tissue-based biomarkers improve patient selection for active surveillance, but require further standardization for widespread clinical use.
Area Of Science
- Oncology
- Urology
- Genomics
Background
- Prostate cancer (PCa) is a global health concern, with conventional treatments causing significant side effects.
- Evolving understanding of PCa natural history necessitates advanced management options.
Purpose Of The Study
- To review the role of active surveillance (AS) in prostate cancer management.
- To highlight the importance of tissue-based biomarkers in refining AS patient selection and risk stratification.
Main Methods
- Review of current literature on prostate cancer management strategies.
- Analysis of the utility and challenges of tissue-based biomarkers in AS.
Main Results
- Active surveillance (AS) is increasingly favored for very low to favorable intermediate-risk PCa.
- Tissue-based biomarkers (e.g., ProMark, Prolaris, GPS, Decipher) enhance patient selection for AS.
- Biomarkers provide crucial prognostic information, aiding treatment decisions and reducing overtreatment.
Conclusions
- Tissue-based biomarkers are vital for optimizing AS in prostate cancer.
- Further standardization and validation are necessary for broad clinical adoption of these biomarkers.
- Improved risk stratification through biomarkers leads to better-informed treatment choices and patient outcomes.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.